News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Articles|March 5, 2010

CN News twitter feed

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

Human Coaching Via Mobile App May Reduce Postgastrectomy Symptoms

ByRoman Fabbricatore

December 30th 2025

Data from a phase 2 study may support a novel mTOR inhibitor-based regimen in previously treated, HR-positive, HER2-negative breast cancer.

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

December 30th 2025

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

December 29th 2025

Janjigian Provides Perspective on Durvalumab Combo Approval in Gastric/GEJ Cancer

ByAriana Pelosci

December 29th 2025

Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, discussed the top hematologic oncology abstracts from the 2025 ASH Annual Meeting and Exposition.

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

ByRahul Banerjee, MD, FACP,Brooke Adams, PharmD, BCOP

December 29th 2025

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer